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Acquired Resistance to BRAF Inhibition Can Confer
Cross-Resistance to Combined BRAF/MEK Inhibition
Kavitha Gowrishankar1, Stephanie Snoyman1, Gulietta M. Pupo1, Therese M. Becker1, Richard F. Kefford1
and Helen Rizos1
Aberrant activation of the BRAF kinase occurs in B60% of melanomas, and although BRAF inhibitors have
shown significant early clinical success, acquired resistance occurs in most patients. Resistance to chronic BRAF
inhibition often involves reactivation of mitogen-activated protein kinase (MAPK) signaling, and the combined
targeting of BRAF and its downstream target MAPK/ERK kinase (MEK) may delay or overcome resistance. To
investigate the efficacy of combination BRAF and MEK inhibition, we generated melanoma cell clones resistant
to the BRAF inhibitor GSK2118436. These BRAF inhibitor–resistant sublines acquired resistance through several
distinct mechanisms, including the acquisition of activating N-RAS mutations and increased accumulation of
COT1. These alterations uniformly promoted MAPK reactivation and most conferred resistance to MEK
inhibition and to the concurrent inhibition of BRAF and MEK. These data indicate that melanoma tumors are
likely to develop heterogeneous mechanisms of resistance, many of which will confer resistance to multiple
MAPK inhibitory therapies.
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INTRODUCTION
Constitutively activating mutations in the serine/threonine
kinase BRAF are found in a large proportion of metastatic
melanomas (Davies et al., 2002; Long et al., 2011). The
majority of these mutations result in a single amino-acid
substitution of valine by glutamic acid at amino acid 600, and
this leads to a 500-fold increase in the kinase activity of BRAF
(Davies et al., 2002; Wan et al., 2004). As a result, most
melanomas display a dependency on the RAF/MEK/ERK
mitogen-activated protein kinase (MAPK) pathway, as shown
by early clinical success with the RAF-targeted inhibitors
Vemurafenib (PLX4032) and GSK2118436 (Flaherty et al.,
2010; Kefford et al., 2010).
Despite the marked initial responses to BRAF inhibitors,
tumor regrowth occurs in most patients (Kefford et al., 2010),
with a median progression-free survival of 5.3 months
(Flaherty et al., 2010; Chapman et al., 2011). Resistance to
chronic BRAF inhibition involves reactivation of MAPK
signaling and/or induction of prosurvival signals. For in-
stance, a subset of BRAF inhibitor–resistant melanoma tumors
restored MAPK activity by expressing truncated forms of
BRAF or by elevating the expression of the serine/threonine
kinases BRAF, CRAF, or COT1 (Montagut et al., 2008;
Corcoran et al., 2010; Johannessen et al., 2010; Poulikakos
et al., 2011). Similarly, activating mutations in N-RAS (Q61K/
R) and MEK1 (C121S) triggered phosphorylated extracellular
signal–regulated kinase (p-ERK) signaling in BRAF inhibitor–-
resistant cell lines and clinical samples (Nazarian et al., 2010;
Wagle et al., 2011). Moreover, the persistent expression of
the receptor tyrosine kinases platelet-derived growth factor
receptor-b (PDGFRb) and IGF-1R conferred BRAF inhibitor
resistance in a MAPK-independent manner that may involve
enhanced phosphatidylinositol 3-kinase (PI3K)/AKT pathway
activation (Nazarian et al., 2010; Villanueva et al., 2010; Shi
et al., 2011). In line with these data, PTEN (phosphatase and
tensin homolog) loss also activated PI3K/AKT signaling and
conferred partial resistance to BRAF inhibition in BRAFV600E-
positive melanoma cell lines (Paraiso et al., 2011).
Importantly, recent studies indicate that MAPK reactiva-
tion can modulate sensitivity to MAPK/ERK kinase (MEK)
inhibition. For instance, melanoma cell lines harboring
oncogenic N-RAS were sensitive to MEK inhibitors (Montagut
et al., 2008; Nazarian et al., 2010), whereas tumor cells
expressing mutant MEK1 or COT1 were refractory to MEK
inhibition and maintained ERK phosphorylation in the
presence of these inhibitors (Emery et al., 2009; Johannessen
et al., 2010). There are currently limited data available on the
activity of combining BRAF and MEK inhibitors, although the
concurrent use of these inhibitors overcame resistance to
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single agents in the setting of MEK mutations and COT1
overexpression (Emery et al., 2009; Johannessen et al., 2010).
In this report, we demonstrate that distinct mechanisms of
acquired resistance to BRAF inhibition can originate from a
single melanoma tumor cell. These resistance drivers
included the acquisition of activating N-RAS mutations and
increased accumulation of COT1. These distinct alterations
uniformly reactivated MAPK signaling and typically con-
ferred cross-resistance to MEK inhibitors and the combination
of MEK and BRAF inhibitors. These data indicate that
melanoma tumors from a single patient are likely to develop
heterogeneous mechanisms of resistance, many of which will
confer resistance to multiple MAPK inhibitory therapies.
RESULTS
Generation of melanoma cell clones with acquired resistance
to the RAF kinase inhibitor GSK2118436
To examine acquired resistance to the potent and highly
selective BRAF kinase inhibitor, GSK2118436 (GSK-BRAFi),
we generated resistance in the MelRMu human melanoma–-
derived cell line (Jiang et al., 2010). This cell line harbors
activating mutations in BRAF (V600E), EGFR (P753S), and
CDK4 (R24C), and is exquisitely sensitive to BRAF inhibition
(half-maximal inhibitory concentration (IC50) 6 nM; Figure
1a). As expected, MelRMu cells responded to increasing
concentrations of GSK-BRAFi by undergoing a G1 cell cycle
arrest followed by potent apoptosis (Figure 1b and c). The
BRAF inhibitor–induced proliferative arrest was associated
with activation of the retinoblastoma protein (pRb; i.e, loss of
hyperphosphorylated and total pRb), accumulation of the
CDK inhibitor p27Kip1, and loss of cyclin D1 expression.
Importantly, activation of pRb and cell cycle arrest was
preceded by decreases in p-ERK that were detectable within
1 hour and up to 24 hours after exposure to GSK-BRAFi
(Figure 1d).
At 5 weeks after continuously exposing MelRMu cells to
100 nM GSK-BRAFi, single cell–derived drug-resistant clones
emerged at a frequency ofB1 in 105 cells. Five of these drug-
resistant (DR) clones (DR2, 4, 6, 8, and 9) were expanded and
characterized. All five DR clones retained the activating
BRAF, EGFR, and CDK4 mutations found in the parental line
(data not shown) and showed strong resistance to GSK-BRAFi
(Figure 2a) with IC50 not reached at 1,000 nM (data not
shown). In all resistant DR clones, MAPK reactivation was
confirmed using protein and gene expression analyses; p-ERK
expression was maintained in the presence and absence of
the drug (Figure 2b), and the resistant sublines demonstrated
a MEK/ERK transcriptome signature indicative of persistent
MEK/ERK activation (Dry et al., 2010; Nazarian et al., 2010;
Figure 2c). This gene set included many known transcription
targets of ERK signaling, including MYC, ETV5, and the
negative feedback regulators DUSP4/6 and SPRY1/2. As a
result, the DR clones responded to BRAF inhibition with a
continued, although somewhat slower, rate of proliferation
(data not shown), with little evidence of GSK-BRAFi-induced
cell death (Figure 2d). Notably, although DR clones survived
in response to BRAF inhibition, they all showed evidence of
reduced S-phase entry that was associated with p27Kip1
accumulation and reduced levels of cyclin D1 (Figure 2b).
Analyses for mutations in the candidate oncogenes H-RAS,
K-RAS, N-RAS, BRAF, and KIT revealed that MelRMu DR2
and DR6 sublines carried the N-RASQ61H-activating mutation
at a frequency of B30%. This mutation was not detected in
the parental MelRMu cell line. Concordant with these data,
unsupervised clustering of differential gene expression
profiles showed that DR2 and DR6 share characteristics
and group away from the parental and other DR clones
(Supplementary Figure S1 online).
We also noted that PTEN expression was retained, CRAF
levels were not substantially elevated (Figure 3a), and
truncated variant forms of BRAF were not detected in the
DR sublines (Supplementary Figure S2 online). Furthermore,
although AKT was activated (increased p-AKT) and PDGFRb
expression was elevated in the DR8 and DR9 sublines
(Figure 3a), these clones did not show activation-associated
PDGFRb phosphorylation in a phospho-RTK array or western
immunoblotting (detailed analyses of DR9 are shown in
Figure 3b), and they did not display an increased PDGFRb-
specific gene signature (Wu et al., 2008; Nazarian et al.,
2010; Supplementary Figure S3 online). Finally, the con-
current inhibition of MAPK with PI3K/mammalian target of
rapamycin (mTOR; BEZ235) or PDGFRb (imatinib mesylate)
did not trigger DR9 cell death (Figure 3c). Collectively, these
data suggest that neither PDGFRb nor the PI3K pathway
mediate BRAF inhibitor resistance in the DR9 subline. The
DR4 cell clone displayed elevated expression of the COT1
kinase (Figure 3a), and in accordance with a recent report
100
a b
c d
R
el
at
iv
e 
vi
ab
ilit
y
(pe
rce
nta
ge
 of
 co
ntr
ol)
80
80 100
MelRMu
M
el
R
M
u60
60
40
40
20
20
0
0
GSK-BRAFi (nM)
Annexin V-APC
PI
GSK-BRAFi 0 nM 100 nM
0 nM 100 nM
Time (hours)
100 nM GSK-BRAFi
0 1 4 24 48 72
p-ERKY204
p27Kip1
p-pRbS807/811
β-Actin
Cyclin D1
Total ERK
Total pRb
G1:
S:
G2/M: 
G1:
S:
G2/M: 
62±2 90±2
7±1
4±1
0±
1
48
±3
29±0
10±1
9±0 3±0 1±0 8±1
78±914±101±088±2
Figure 1. Analysis of the BRAF inhibitor–sensitive MelRMu melanoma cell
line. (a) Viability curve for MelRMu cell line treated with increasing
concentrations of GSK-BRAFi for 72 hours (relative to DMSO-treated controls;
mean±SD; n¼ 3). (b) Cell cycle distribution of MelRMu cells treated with
either DMSO (0 nM) or GSK-BRAFi (100 nM) for 72 hours. (c) Dual-color flow
cytometric Annexin V analysis for apoptosis of MelRMu cells treated with
DMSO (0 nM) or GSK-BRAFi (100 nM) for 72 hours. APC, allophycocyanin; PI,
propidium iodide. (d) MelRMu cells were treated with 100 nM GSK-BRAFi for
increasing duration. The effects on extracellular signal–regulated kinase (ERK)
activation and cell cycle regulators were determined by immunoblotting.
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(Johannessen et al., 2010) short hairpin RNA (shRNA)-
mediated depletion of COT1 cooperated with BRAF inhibi-
tion to suppress DR4 viability, without affecting the sensitivity
of the MelRMu parental line (Figure 3d).
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We then compared the gene expression profiles of the
MelRMu-derived resistant sublines with a signature predictive
of MEK resistance, which appears to be driven upstream of
RAF and independently of RAS or PI3K pathway mutations
(Dry et al., 2010). Although only 6 of the 13 genes in this
published resistance signature mapped to the Illumina
platform, these genes showed significantly increased expres-
sion in the closely related DR8- and DR9-resistant sublines
(Supplementary Figure S4 online). These data indicate that
distinct mechanisms originating from a single melanoma cell
line mediate MAPK reactivation and resistance to BRAF
inhibition.
Activating N-RAS reactivates MAPK and confers resistance
to BRAF inhibition
Activating N-RAS mutations (Q61K and Q61R) have pre-
viously been identified in two biopsy samples derived from
BRAF inhibitor (PLX4032)–resistant melanoma metastases
from a single patient (Nazarian et al., 2010). To thoroughly
examine the role of oncogenic N-RAS in regulating tumor
growth and conferring resistance to BRAF inhibition, we
initially silenced the expression of N-RAS using highly
specific shRNA molecules (Figure 4a). The suppression of
N-RAS in the N-RAS wild-type DR4 and N-RAS mutant DR2
and DR6 sublines did not result in proliferative arrest
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Figure 3. BRAF inhibitor–resistant isogenic MelRMu sublines display distinct mechanisms of acquired resistance. (a) MelRMu parental and BRAF
inhibitor–resistant sublines were treated with DMSO () or 100 nM GSK-BRAFi (þ ) for 24 hours, and the effects on known drug-resistance regulators were
determined by immunoblotting. (b) Phosphorylation of platelet-derived growth factor receptor-b (PDGFRb) was analyzed in the MelRMu parent and DR9
subline using phospho-RTK antibody arrays (left panel) and western immunoblotting (right panel). The positions of phosphorylated EGFR (positive in MelRMu
and DR9) and phosphorylated PDGFRb (negative in MelRMu and DR9) are indicated. DR, drug resistant. (c) Impact of mitogen-activated protein kinase (MAPK)
inhibition (100 nM GSK-BRAFi and 5 nM GSK-MEKi) either alone or in combination with receptor tyrosine kinase inhibition (100 nM imatinib mesylate) or
phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibition (1 mM BEZ235) on cell survival at 72 hours after treatment. The inhibitory
activity of imatinib and BEZ235 on c-Kit and AKT activation was confirmed in the c-Kit mutant (c-KitW557K558) melanoma cell line, MelMS. (d) MelRMu and
DR4 were transfected with COT1 short hairpin RNA (shRNA; þ ) or control () shRNA. At 24 hours after transfection, cells were treated with DMSO () or
100 nM GSK-BRAFi (þ ) for an additional 72 hours. COT1 silencing (right panel) and the effects on cell death (left panel) were measured 72 hours after drug
addition.
Figure 2. Mitogen-activated protein kinase (MAPK) reactivation in cells with acquired resistance to GSK-BRAFi. (a) Viability curves of the parental and
isogenic melanoma MelRMu sublines treated with the indicated GSK-BRAFi concentrations for 72 hours (relative to DMSO-treated controls; mean±SD; n¼ 3).
DR, drug resistant. (b) MelRMu parental cells and BRAF inhibitor–resistant sublines were treated with DMSO () or 100 nM GSK-BRAFi (þ ) for 24 hours, and the
effects on extracellular signal–regulated kinase (ERK) activation and cell cycle regulators were determined by immunoblotting. (c; left panel) Heat map for
MEK/ERK activation signature in each of the cell lines treated with DMSO () or 100 nM GSK-BRAFi (þ ) for 24 hours. Color scale, log2-transformed expression
(red, high; green, low) for each gene (row) normalized by the mean of all samples. The probe ID is shown after each gene symbol. (c; right panel) Histograms
of mean log2-transformed expression of all transcripts included in the MEK/ERK activation signature (see left panel). MEK, MAPK/ERK kinase. (d) GSK-BRAFi
effects on cell cycle distribution and apoptosis. APC, allophycocyanin; PI, propidium iodide.
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(data not shown) or apoptosis in the absence of the BRAF
inhibitor, indicating that these resistant clones did not depend
on N-RAS signaling for growth (Figure 4a). In the presence of
BRAF inhibitor, however, the stable suppression of N-RAS
expression suppressed ERK activation, reinstated sensitivity to
GSK-BRAFi, and resulted in potent cell death in the N-RAS
mutant DR2 and DR6 sublines (Figure 4a and Supplementary
Figure S5 online). This effect was highly specific, as
suppression of N-RAS expression in the parental MelRMu
and DR4 cells (both wild type for N-RAS) had no effect on
GSK-BRAFi sensitivity (Figure 4a and Supplementary Figure
S5 online). Conversely, the stable overexpression of MYC-
tagged N-RASQ61K promoted accumulation of p-ERK and
conferred BRAF inhibitor resistance in the MelRMu parental
cell line (Figure 4b).
Oncogenic N-RAS dampens sensitivity to MEK inhibition
As shown in Figure 3a, activated N-RAS did not activate the
PI3K/AKT pathway in the DR2 and DR6 sublines. Conse-
quently, we predicted that melanoma cells expressing
oncogenic N-RAS signaled predominantly via the reactivated
MAPK pathway and would retain sensitivity to MEK inhibi-
tion. Surprisingly, we found that the pattern of sensitivity to
MEK inhibition, using the allosteric MEK inhibitor
GSK1120212 (GSK-MEKi; Gilmartin et al., 2011), was
significantly diminished in most BRAF inhibitor–resistant
MelRMu DR sublines: GSK-MEKi IC50 o2nM for MelRMu
parental cells (Figure 5a). Critically, the level of resistance to
MEK inhibition paralleled the unsupervised clustering of our
DR clones in genome-wide, differential expression patterns
(Supplementary Figure S1 online). Specifically, both N-RAS
mutant DR2 and DR6 clones showed diminished MEK
inhibitor sensitivity; the DR4 clone (expresses COT1 and
clusters closely with the parental MelRMu line in gene
profiling; Supplementary Figure S1 online) was sensitive to
MEK inhibition and showed effective suppression of ERK
phosphorylation (Figure 5b). The DR8 and DR9 clones, which
are distinct from the other DR clones but share a common
MEK resistance signature (Supplementary Figure S4 online),
were highly resistant to MEK inhibition (Figure 5). Importantly,
all resistant sublines showed minimal cell death in response to
MEK inhibition but displayed a degree of S-phase inhibition
that was associated with reduced cyclin D1 (Figure 5b and c).
Finally, we also showed that the stable overexpression of
MYC-tagged N-RASQ61K conferred MEK inhibitor resistance in
the MelRMu parental cell line (Figure 5d).
Dual inhibition of MEK and BRAF can restore partial sensitivity
of melanoma cells with activating N-RAS and BRAF mutations
MelRMu parental cells were exquisitely sensitive to BRAF
inhibition, and the combination of BRAF and MEK inhibition
enhanced cell death in these cells (Figure 6). Similarly, in the
majority of DR clones, targeting the MAPK pathway at both
the BRAF and MEK nodes increased the percentage of cells
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The effects on phosphorylated extracellular signal–regulated kinase (p-ERK) accumulation were detectable 24 hours after exposure to GSK-BRAFi (left panel),
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undergoing cell death, although this increase never reached
the level of apoptosis seen in the parental cells (Figure 6b).
For example, in response to the combined inhibition of BRAF
and MEK, the N-RAS mutant DR2 and DR6 sublines
displayed a sub-G1 fraction of B20% compared with over
60% sub-G1 cells in the parent melanoma line (Figure 6a and
b). Moreover, ectopic expression of N-RASQ61K in the
MelRMu cells diminished the efficacy of the combination of
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MEK and BRAF inhibition (Figure 6c). Finally, the highly
resistant DR9 subline remained refractory to the simultaneous
inhibition of MEK and BRAF. In line with these data, the
combination of BRAF and MEK inhibition did not signifi-
cantly inhibit MAPK signaling in the DR clones, although the
reduced levels of cyclin D1 and p-pRb (both markers of cell
cycle inhibition) were comparable in the DR clones and
MelRMu parent (Figure 6d).
DISCUSSION
The prevalent acquisition of resistance to BRAF inhibitors is a
major problem in clinical oncology and reflects the capacity
of melanomas to either circumvent their dependence on
MAPK activity or, more commonly, restore MAPK signaling.
For instance, increased expression of the IGF-1R or PDGFRb
receptor tyrosine kinases activates the compensatory PI3K/
AKT survival pathway (Nazarian et al., 2010; Villanueva
et al., 2010). Similarly, alterations that facilitate ERK
activation, such as increased abundance of CRAF or COT1,
activating mutations in MEK or N-RAS, and amplification or
truncation of BRAF, have been identified in vivo and in vitro
(Montagut et al., 2008; Corcoran et al., 2010; Johannessen
et al., 2010; Nazarian et al., 2010; Poulikakos et al., 2011;
Wagle et al., 2011). In this report, we show that MAPK
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reactivation is the predominant mechanism of acquired BRAF
inhibitor resistance, with all resistant melanoma sublines
displaying reactivation and often enhanced MAPK signaling
in the presence of the BRAF inhibitor GSK2118436.
The restoration of MAPK activity in the presence of
BRAF inhibitor, and the observation that tumor regression
requires near-complete cessation of ERK activity, suggests
that the combination of inhibitors targeting multiple nodes in
the MAPK pathway may provide a more durable and
prolonged clinical response (Bollag et al., 2010). Consistent
with this hypothesis, combined MEK and BRAF inhibition
overcame resistance of colorectal cancer cells to MEK or
BRAF inhibitors used singly and was more effective in
parental cells compared with either agent alone (Corcoran
et al., 2010). Moreover, drug trials testing concurrent
therapy with BRAF and MEK inhibitors are underway
in patients with mutant BRAF metastatic melanoma (Infante
et al., 2011).
In this report, the potency of combined MEK and BRAF
inhibition was assessed in a series of melanoma sublines with
resistance to BRAF inhibition. These DR sublines were
generated from a single parental line; although they displayed
distinct mechanisms of resistance, all showed increased
MAPK signal pathway output in the presence of GSK-BRAFi.
The majority of DR clones showed weaker sensitivity to MEK
inhibition alone and to the combination of MEK and BRAF
inhibitors when compared with the parental clone, indicating
that acquiring resistance to BRAF inhibition commonly
confers cross-resistance to MEK inhibitors.
The activation of N-RAS conferred potent resistance to
GSK-BRAFi, but significantly diminished the sensitivity of
melanoma clones to GSK-MEKi alone, or the combination of
MEK and BRAF inhibitors. These data strongly suggest that
activation of N-RAS maintains MAPK signaling in the
presence of BRAF inhibitor, and that additional MEK-
independent N-RAS effectors contribute to MEK and BRAF
inhibitor resistance. It is known that mutant N-RAS uses CRAF
to signal to MEK and ERK, thus bypassing inhibited BRAF
(Dumaz et al., 2006; Jaiswal et al., 2009), and that N-RAS can
signal via multiple pathways including the PI3K/AKT cascade
(Smalley, 2010). Nevertheless, there are discrepancies in the
literature regarding the role of activated RAS in selectively
sensitizing cancer cells to MEK inhibition. In one study, BRAF
inhibitor–resistant melanoma cell lines with an acquired N-
RASQ61K mutation were sensitive to MEK inhibition in the
presence of the RAF inhibitor, Vemurafenib/PLX4032 (Na-
zarian et al., 2010). Conversely, N-RAS mutation status did
not predict MEK inhibitor sensitivity in melanoma cell lines
(Solit et al., 2006), and MEK inhibitors show only modest
clinical activity in patients with RAS-mutant tumors (Nissan
and Solit, 2011). It seems likely that the impact of mutant RAS
on MEK inhibitor responses reflects its expression and activity
and ultimately the network of activated N-RAS-dependent
effectors. This is in agreement with a recent report
demonstrating that K-RAS13D-mutant HCT116 colorectal
cancer cells became resistant to MEK inhibition upon
amplification of the driving K-RAS13D oncogene (Little
et al., 2011).
The DR8 and DR9 sublines showed constitutive reactiva-
tion of MAPK signaling, elevated levels of PDGFRb, and
activation of AKT. There was no evidence of activation-
associated PDGFRb phosphorylation, and thus this receptor
tyrosine kinase did not contribute to AKT activity or BRAF
inhibitor resistance in these clones. Signaling via AKT was
also not mediating resistance, as the combined inhibition of
MAPK (BRAFþMEK), PI3K, and mTOR did not trigger
apoptosis in the DR8 and DR9 clones. In contrast, melanoma
cells with PDGFRb activation did not show significant
reactivation of MAPK signaling (Nazarian et al., 2010), and
the concurrent inhibition of the MAPK and PI3K/AKT/mTOR
pathways overcame resistance to the BRAF inhibitor,
Vemurafenib (Shi et al., 2011). The dual targeting of BRAF
and the PI3K network appears effective when BRAF
inhibition leads to increased AKT phosphorylation, a
compensatory prosurvival mechanism not observed in
any of our DR clones (Atefi et al., 2011; Sanchez-
Hernandez et al., 2012). The DR4 subline differed
significantly in retaining some sensitivity to MEK inhibi-
tion, in the absence and presence of BRAF inhibitor. This
presumably reflects the fact that DR4 accumulates elevated
levels of the COT1 kinase, which activates ERK through
MEK-dependent and -independent mechanisms (Johannes-
sen et al., 2010).
Our study confirms that many perturbations restoring
MAPK activation have the potential to cause resistance to
MEK inhibition and to the concurrent inhibition of BRAF and
MEK. These data are in agreement with a recent report
showing a high degree of cross-resistance to BRAF and MEK
inhibitors in BRAF inhibitor–resistant melanoma cell lines
generated in vitro (Ribas et al., 2010). Furthermore, experi-
mental and computational modeling of the MAPK pathway
showed that switching activated ERK from BRAF to CRAF is
accompanied by increased resistance to MEK inhibition
(Sturm et al., 2010). The clinical significance of these
findings will require validation, and it remains unclear
whether initial combination therapy with MEK and RAF
inhibitors yields improved efficacy over single agents in
terms of the frequency and duration of response. What is
becoming increasingly evident, however, is that individua-
lized combinations of highly targeted agents affecting
multiple signaling pathways will be required to overcome
the complex and heterogeneous resistance networks in
melanoma metastases.
MATERIALS AND METHODS
Cell culture and compounds
MelRMu and MelMS melanoma cells were obtained from Professor
P Hersey (Newcastle, NSW, Australia). Cells were grown in DMEM
with 10% fetal bovine serum and glutamine (Gibco BRL, Carlsbad,
CA). Cells were cultured in a 37 1C incubator with 5% CO2. Stocks
of GSK-BRAFi and GSK-MEKi (GlaxoSmithKline, Collegeville, PA),
BEZ235, and imatinib mesylate (Selleck Chemicals, Houston, TX)
were prepared in DMSO. Cell authentication was confirmed using
the AmpFlSTR Identifiler PCR Amplification Kit from Applied
Biosystems (Mulgrave, Victoria, Australia), and using the Gene-
Marker V1.91 software (SoftGenetics, State College, PA).
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Pharmacological growth inhibition assays
Cultured cells were seeded into 96-well plates (1,000 cells per well)
and 24 hours after seeding serial dilutions of the relevant compound
prepared in media were added. Cells were incubated for 72 hours,
and cell viability was measured using the Cell proliferation Aqueous
MTS assay (Promega, Wisconsin, MD) on a VICTOR2 Multilabel
counter (Perkin Elmer, Waltham, MA). Viability was calculated as a
percentage of control (DMSO-treated cells) after background
subtraction. A minimum of two independent viability assays each
performed in triplicate was carried out for each cell line and drug
combination.
Cell cycle and apoptosis analysis
Adherent and floating cells were combined and cell cycle
and apoptosis analyses were performed as previously described
(Gallagher et al., 2005).
DNA extraction and genotyping
Genomic DNA was extracted from 1–2 106 cells using the Wizard
SV Genomic DNA purification system (Promega). MelRMu cells
were genotyped as part of the Sequenom OncoCarta Assay Panel
v1.0 (San Diego, CA).
RNA extraction and microarray gene expression analysis
Total RNA was extracted as described previously (Scurr et al., 2010).
Gene expression analysis was performed using the Sentrix Human-
Ref-6 v.4.0 Expression BeadChip (Illumina, San Diego, CA) and
BeadStation system from Illumina according to the manufacturer’s
instructions.
Protein detection
Total cellular proteins were extracted at 4 1C using RIPA lysis buffer
containing protease and phosphatase inhibitors (Roche, Basel,
Switzerland). Proteins (40 mg) were resolved on 12% SDS-PAGE
and transferred to Immobilon-P membranes (Millipore, Bedford,
MA). Phospho-RTK arrays were performed according to the
manufacturer’s instructions (Human Phospho-RTK Array Kit; R&D
Systems, Minneapolis, MN). Western blots were probed with
antibodies against p-ERK (E4; Santa Cruz Biotechnology, Santa
Cruz, CA), total ERK (137F5; Cell Signaling, Danvers, MA), BRAF
(L12G7 and 55C6, Cell Signaling), pRbS807/811 (Cell Signaling), total-
pRb (G3-245, Becton Dickinson, Franklin Lakes, NJ), b-actin (AC-74;
Sigma-Aldrich), p27Kip1 (Becton Dickinson), p16INK4a (JC8, Santa
Cruz Biotechnology), cyclin D1 (G124-326, Becton Dickinson),
CRAF (E10, Santa Cruz Biotechnology), N-RAS (F155, Santa Cruz
Biotechnology), pAKTS473 (736E11, Santa Cruz Biotechnology), total
AKT (11E7, Cell Signaling), PTEN (A2B1, Santa Cruz Biotechnology),
COT/Tpl2 (Cell Signaling), IGF-1R (Cell Signaling), pPDGFRbY751
(88H8, Cell Signaling), and PDGFRb (C82A3, Cell Signaling).
Lentiviral transductions
Lentiviruses were produced in HEK293T cells as described
previously (Haferkamp et al., 2009). Cells were infected using a
multiplicity of infection of 5 to provide an efficiency of infection
above 90%. For N-RAS silencing experiments, cells were transduced
with control-pSIH-copGFP or N-RAS-pSIH-copGFP for 5 days.
Inhibitors or DMSO were added and cells were harvested 72 hours
after inhibitor treatment for cell cycle and western blot analyses.
The shRNA no.1 and 2 sequences targeting N-RAS correspond to
nucleotides 567–586 and 741–759 (NM_002524.3), respectively.
The COT1 shRNA sequence corresponds to nucleotides 1826–1846
(NM_005204.2), and the non-silencing negative control shRNA did
not show complete homology to any known human transcript and
had the following sequence: 50-TTAGAGGCGAGCAAGACTA-30.
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